Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary

Balint Gergely Szabo · Katalin Szidonia Lenart · Borisz Petrik · Zsofia Gaspar · Noemi Kiss-Dala · Janos Szlavik · Istvan Valyi-Nagy · Botond Lakatos · Saint Ladislaus COVID-19 Collaborative

Received: 5 June 2021 / Accepted: 23 August 2021 / Published online: 3 September 2021

© The Author(s) 2021

Abstract Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was performed among adults hospitalized at our center between March and August 2020 with moderate-to-severe, PCR-confirmed COVID-19. For diagnosis and severity, ECDC and WHO definitions were utilized. Patients were screened for inclusion by a priori criteria and included in the FVP cohort if standard-of-care (SOC) + FVP or the non-FVP cohort if SOC ± other antivirals without FVP were administered for > 48 h from diagnosis. Treatment allocation was done per national guidelines, based on severity and drug availability. Primary endpoint was disease progression, a composite of 14-day all-cause death, need for mechanical ventilation, or immunomodulatory therapy. The impact of FVP exposure on disease progression was analyzed by binomial logistic regression. In all, 150 patients were included, 75 in each cohort. Disease progression (17/75, 22.7% vs. 10/75, 13.3%, \( p = 0.13 \)), 14-day all-cause death (9/75, 12.0% vs. 10/75, 13.3%, \( p = 0.8 \)), and need for mechanical ventilation (8/75, 10.7% vs. 4/75, 5.3%, \( p = 0.22 \)) were similar, while immunomodulatory therapies were required more frequently among patients receiving FVP (10/75, 13.3% vs. 1/75, 1.3%, \( p < 0.01 \)). The use of favipiravir was not retained as a protective factor against disease progression in multivariate analysis. Time to antiviral therapy from PCR positivity, disease severity, need for oxygen supportation, and ICU admittance rates did not differ statistically between cohorts. In this study, favipiravir did not seem to positively affect disease progression.

Keywords SARS-CoV-2 · COVID-19 · Favipiravir · Antiviral

Abbreviations

ARDS Acute respiratory distress syndrome
COVID-19 Coronavirus disease-19
CRP C-reactive protein
CT Computed tomography
As the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing, investigators are searching for therapeutic strategies against coronavirus disease-19 (COVID-19). As of April 2021, the number of antiviral drugs proven to inhibit viral replication in vivo is low [1]. Favipiravir (FVP) is a pyrazinocarboxamide derivative, licensed for influenza treatment in Japan since 2014. Literature data suggested that favipiravir might be useful for COVID-19 treatment. During in vitro studies, FVP demonstrated inhibitory activity against SARS-CoV-2. Also, early clinical experience from two trials recruiting adult inpatients documented favorable therapeutic responses with FVP in terms of recovery and viral clearance [2–5]. These results highlighted the need for further data concerning the place of favipiravir among COVID-19 treatment strategies. In Hungary, favipiravir was one of the drugs approved for clinical use as an experimental medication during the first wave on May 15, 2020. Our goal was to assess the effect of favipiravir on the clinical course of moderate-to-severe COVID-19 among inpatients.

Methods

Study design and settings

A prospective sequential cohort study was performed among consecutive adult (age ≥ 18 years) patients diagnosed and hospitalized with COVID-19 between March and August 2020 at our center. The first COVID-19 case was confirmed in March 4 in Hungary. Our center is a national-level referral institution of COVID-19 with > 150 dedicated beds. The study was in accordance with the Helsinki Declaration and national ethical standards. The institutional review board of our center approved the study protocol. During the first wave of the COVID-19 pandemic, a randomized study design was not ethically feasible. Approval for the use of off-label antiviral drugs was granted by the National Institute of Pharmacy and Nutrition and the institutional review board. Informed consent was obtained from each patient.

Patient eligibility and inclusion

Patients hospitalized at our center during the study period with COVID-19, confirmed by respiratory SARS-CoV-2 polymerase chain reaction (PCR), were eligible for inclusion, irrespective of COVID-19 severity. To overcome selectional bias, all patients were screened for inclusion during daily real-time ward and intensive care unit (ICU) visits by our COVID-19 team, composed of attending physicians. Selection was done by using a priori inclusion/exclusion criteria after diagnosis establishment. Inclusion criteria are as follows: (1) moderate-to-severe COVID-19, confirmed by PCR, and (2) administration of standard-of-care (SOC) or any antiviral treatment exposures for > 48 h after diagnosis. Exclusion criteria are as follows: (1) the patient was intubated, died, or discharged within ≤ 48 h after diagnosis; (2) received SOC or any antiviral treatment exposures for ≤ 48 h after diagnosis; (3) received any other antiviral medication (e.g., against HIV, HBV, or HCV) before diagnosis; or (4) patient data was inaccessible through hospital electronic databases.

Included patients were grouped in a 1:1 proportion into two sequential “before/after” cohorts, according to favipiravir availability: FVP cohort consisted of patients receiving SOC + FVP (after availability), non-favipiravir (non-FVP) cohort included patients who were administered SOC + other antiviral medications (before availability). Possible non-FVP antiviral medications at study design: chloroquine/hydroxychloroquine, lopinavir/ritonavir, or remdesivir (see below for details).
Data collection

A database was established for the study aim by manual data extraction from hospital electronic records and written charts. Anonymized data were transferred to a standardized case report form. Data collected are as follows: (1) age and gender; (2) comorbidities; (3) ICU admission, length of stay (LOS), and ICU LOS; (4) baseline clinical parameters (symptom onset, COVID-19 severity, oxygen demand, peripheral oxygen saturation, acute respiratory distress syndrome [ARDS], cytokine storm, acute respiratory failure); (5) baseline laboratory parameters (absolute neutrophil granulocyte and lymphocyte counts, CRP, procalcitonin, serum ferritin, high-sensitivity cardiac troponin-I, serum interleukin-6 [IL-6], serum creatinine, LDH, and D-dimer); (6) baseline microbiological and radiological parameters (blood cultures and chest computed tomography [CT]); (7) antimicrobial, immunomodulatory therapies, and supportive care during hospitalization; (8) outcomes. Baseline characteristics were established at COVID-19 diagnosis. Variables with ≥5% of missing measurements were omitted from analysis.

Diagnostic and therapeutic strategies at our center during the first wave

At our center, we followed the European Centre for Disease Prevention and Control (ECDC) COVID-19 case definition for diagnosis ascertainment: a clinically suspicious case (usual symptoms: fever, dyspnea, cough) was confirmed if a respiratory specimen was positive for SARS-CoV-2 nucleic acid by PCR [6]. Respiratory specimens were taken by trained nurses with nasopharyngeal sampling in spontaneously breathing patients or blind bronchoalveolar lavage in ventilated patients. Disease severity was determined by the World Health Organization (WHO) criteria [7]. Disease onset was the first day of patient-reported typical symptom appearance, or day of first PCR positivity, if symptoms could not be reported. The day of first SARS-CoV-2 PCR positivity was given as COVID-19 diagnosis day. Acute respiratory failure and ARDS were defined by 2012 Berlin criteria. Cytokine storm was diagnosed by a compatible case presentation (persistent fevers for ≥72 h, deteriorating hypoxaemia) with serum ferritin ≥600 µg/l, serum IL-6 ≥3× and LDH level ≥1× above the upper limit-of-normal, or a HScore of ≥250 [8–10]. COVID-19 patient care was facilitated by standardized and regularly updated in-house protocols since March 2020. Physical examination, laboratory studies, and arterial blood gas analyses were done daily. Chest X-ray and/or chest CT were executed on COVID-19 diagnosis day, and if clinical instability (newly onset dyspnea, chest pain, hypotension, altered mentation) was documented. Febrile patients had 2 sets of blood cultures taken. Fever was defined as a tympanal temperature ≥37.8 °C. Patient follow-up was done daily until death or hospital discharge. All microbiological diagnostics were performed at the microbiology laboratory of our center.

Anti-SARS-CoV-2 antiviral therapies were allocated per protocol according to COVID-19 disease severity in an open-label, non-randomized fashion. Treatment allocation was done in accordance with the “Hungarian Coronavirus Handbook,” and was affected by national drug availability [11]. Before favipiravir introduction, all inpatients with moderate-to-severe COVID-19 received other medications: chloroquine (1 g loading dose and 1×500 mg maintenance, 7 days minimum), hydroxychloroquine (2×400 mg loading dose and 2×200 mg maintenance, 5 days minimum), and lopinavir/ritonavir (200/50 mg in 2×2 capsules, 7 days minimum), depending on availability and contraindications. Although remdesivir was recommended in the protocol, it was not available in Hungary during the study period. All patients received favipiravir monotherapy after national distribution (2×1600 mg loading dose and 2×600 mg maintenance, 10 days minimum). Immunomodulatory drugs administered to patients with cytokine storm or critical COVID-19 were tocilizumab, ruxolitinib, baricitinib, intravenous immunoglobulin, convalescent plasmatherapy, or systemic corticosteroids. SOC included on-demand oxygen therapy, respiratory support, intravenous fluid replacement, antipyretics, antitussive, and bronchodilator drugs. All patients were given SOC independently from antiviral therapies. Empirical antibiotics according to Infectious Diseases Society of America (IDSA) community-acquired pneumonia guideline were initiated per decision of the attending physician, if clinical instability was documented and a bacterial cause could not be ruled out [12].
Outcomes

Primary outcome was disease progression during COVID-19 treatment, a composite endpoint of any of the following: (1) 14-day all-cause death, (2) need for mechanical ventilation, (3) need for immunomodulatory therapy for COVID-19. Fourteen-day all-cause death was defined as exitus within 14 days from COVID-19 diagnosis during hospitalization. Need for mechanical ventilation was defined as endotracheal intubation in relation to COVID-19, per decision of an ICU crash team. Need for immunomodulatory therapy was defined if any immunomodulatory drug was initiated at any dose, excluding systemic corticosteroids started for alternative causes.

Secondary endpoints were 14-day all-cause mortality, need for mechanical ventilation, and need for immunomodulatory therapy (at hospital discharge or sooner). Analyses were done by comparing time intervals from COVID-19 diagnosis day to disease progression, all-cause mortality, mechanical ventilation, and immunomodulatory therapy.

Statistical analysis

Continuous variables are expressed as median± interquartile range (IQR). Categorical variables are expressed as absolute numbers (n) with relative percentages (%). Statistical comparisons were done with Mann–Whitney U-test or Fisher’s exact test. Normality was checked with Shapiro–Wilk test. For identification of independent risk factors associating with disease progression, univariate and multivariate binomial logistic regression was performed. Plausible parameters and those with a  \( p \)-value ≤ 0.1 in univariate analysis were entered into forward-stepwise multivariate logistic regression (entry criterion:  \( p = 0.05 \), removal criterion:  \( p = 0.1 \)). Maximal predictor number was estimated with the 1:10 rule-of-thumb; goodness-of-fit was tested by Hosmer–Lemeshow test. A two-tailed  \( p \)-value < 0.05 determined statistical significance. Tests were calculated using IBM SPSS Statistics 23. For reporting, we adhered to Strengthening the Reporting of Observational studies in Epidemiology (STROBE) Statement [13].

Results

Baseline and clinical characteristics

In all, 150 patients were enrolled, 75 in both cohorts. Baseline and clinical characteristics are described in Table 1. Median age was 66.0±12.4 years, with representation of older patients in the FVP cohort (71.5±15.1 vs. 61.0±21.5 years,  \( p = 0.01 \)). Genders and most comorbidities were equally distributed between cohorts, while chronic heart disease (36/75, 48.0% vs. 16/75, 21.3%,  \( p < 0.01 \)) and diabetes mellitus (18/75, 24.0% vs. 6/75, 8.0%,  \( p = 0.01 \)) were prevalent in the FVP cohort. At diagnosis, 35/75 (53.3%) and 41/75 (54.7%) patients had severe disease ( \( p = 0.41 \)); ARDS or cytokine storm was not documented. Need for oxygen supportation (27/75, 36.0% vs. 21/75, 28.5%,  \( p = 0.29 \)), and rates of ICU admission (12/75, 16.0% vs. 5/75, 6.7%,  \( p = 0.07 \)) did not differ statistically between cohorts during hospitalization. Bloodstream-infections were rare (1/75, 0.7%). Between cohorts, laboratory parameters were comparable, and chest CT positivity rate did not show statistical difference (54/64, 84.4% vs. 13/14, 92.8%,  \( p = 0.67 \)).

Outcomes and therapeutic approaches

Outcomes and therapeutic approaches are detailed in Table 2. Disease progression showed no statistically significant difference between cohorts (17/75, 22.7% vs. 10/75, 13.3%,  \( p = 0.13 \)). Rates of 14-day all-cause mortality (9/75, 12.0% vs. 10/75, 13.3%,  \( p = 0.8 \)) and need for mechanical ventilation (8/75, 10.7% vs. 4/75, 5.3%,  \( p = 0.22 \)) were also similar. The need for any immunomodulatory therapy was higher in the FVP cohort (10/75, 13.3% vs. 1/75, 1.3%,  \( p < 0.01 \)). Also, both median time from diagnosis to disease progression (8.0±9.0 days vs. 4.5±9.8,  \( p = 0.08 \)) and to exitus (16.0±14.0 days vs. 8.5±10.3 days,  \( p = 0.03 \)) were longer among these patients. In the non-FVP cohort, patients usually received chloroquin or hydroxycchloroquin. Frequently administered antibiotics were azithromycin (19/75, 25.3% vs. 44/75, 58.7%,  \( p < 0.01 \)) and ceftriaxon (13/75, 17.3% vs. 28/75, 37.3%,  \( p < 0.01 \)), while most tocilizumab was given to patients with cytokine storm (9/75, 12.0% vs. 1/75, 1.3%,  \( p = 0.01 \)). Supportive therapies detailed in Table 2 are required in statistically similar
rates among cohorts (43/75, 57.3% vs. 46/75, 61.3%, p = 0.73). Favipiravir exposure was not retained as an independent protective factor in multivariate regression for disease progression (Table 3).

Discussion

Present study

We performed a prospective sequential cohort study by enrolling 150 hospitalized adult patients with moderate-to-severe COVID-19, receiving either favipiravir or other antiviral medications with standard-of-care during the first wave of the SARS-CoV-2 pandemic in Hungary. There were no statistically significant differences in time to antiviral therapy initiation from PCR positivity. COVID-19 disease severity, need for oxygen supportation, and ICU admittance rates between cohorts. Disease progression, 14-day all-cause mortality, and need for invasive mechanical ventilation were unaffected by favipiravir exposure, compared to other antivirals. Surprisingly, there was higher demand for immunomodulatory therapies among patients receiving favipiravir. Finally, favipiravir was not proven as a protective factor against disease progression in multivariate analysis.

Studies from the current literature

Pharmacological approaches and clinical studies describing favipiravir treatment strategies for COVID-19 patients were reported in the literature.
Although favipiravir demonstrated good in vitro inhibitory activity against SARS-CoV-2, the optimal dose for COVID-19 treatment has yet to be determined, as recommendations are based on pharmacokinetic experiments and earlier clinical trials. Doses extrapolated from studies involving patients with other viral infections (influenza virus, Ebola virus) might be insufficient to maintain adequate serum concentrations, especially in critically ill patients [2, 14, 15]. Although a review found that favipiravir has a favorable safety profile concerning serious adverse events, the main side effects are hyperuricaemia, teratogenicity, and QTc prolongation. Establishment of long-term safety profile

Table 2 Outcomes and therapeutic approaches to adult COVID-19 patients included in the study, grouped by favipiravir administration

| PARAMETER | Total (n=150) | FVP cohort (n=75) | Non-FVP cohort (n=75) | p value |
|-----------|--------------|------------------|----------------------|---------|
| Disease progression (n, %) | 27 (18.0) | 17 (22.7) | 10 (13.3) | 0.13 |
| 14-day all-cause mortality (n, %) | 19 (12.7) | 9 (12.0) | 10 (13.3) | 0.8 |
| Need for invasive mechanical ventilation (n, %) | 12 (8.0) | 8 (10.7) | 4 (5.3) | 0.22 |
| Need for immunomodulatory therapy (n, %) | 13 (8.7) | 10 (13.3) | 3 (4.0) | <0.01 |
| Time from diagnosis to disease progression (days, median, IQR, min–max) | 7.0±7.0 (1.0–14.0) | 8.0±9.0 (3.0–14.0) | 4.5±5.8 (1.0–12.0) | 0.08 |
| Time from diagnosis to death (days, median, IQR, min–max) | 12.0±7.5 (1.0–50.0) | 16.0±14.0 (6.0–50.0) | 8.5±10.3 (2.0–14.0) | 0.03 |
| Time from diagnosis to mechanical ventilation (days, median, IQR, min–max) | 4.5±5.3 (1.0–12.0) | 5.5±5.3 (3.0–12.0) | 4.5±3.5 (1.0–12.0) | 0.79 |
| Time from diagnosis to immunomodulatory therapy (days, median, IQR, min–max) | 7.0±5.5 (3.0–14.0) | 7.0±6.0 (3.0–14.0) | 4.0±1.0 (4.0–4.0) | 1.0 |
| LOS (days, median, IQR, min–max) | 15.0±10.8 (2.0–49.0) | 18.5±15.5 (3.0–49.0) | 13.0±8.5 (2.0–40.0) | <0.01 |
| ICU LOS (days, median, IQR, min–max) | 5.0±2.0 (1.0–25.0) | 5.0±2.0 (2.0–12.0) | 5.0±3.0 (1.0–25.0) | 0.79 |

Antiviral therapies given (n, %):
- Favipiravir | 75 (50.0) | 75 (100.0) | – |
- Chloroquine/dihydroxychloroquine | 66 (44.0) | 5 (6.7) | 61 (81.3) | n.a. |
- Lopinavir/ritonavir | 7 (4.7) | 0 | 7 (9.3) |
- Remdesivir | 0 | 0 | 0 |

Antibacterial therapies given (n, %):
- Ampicillin | 1 (0.7) | 1 (1.3) | 0 | 0.31 |
- Amoxicillin/clavulanate | 5 (3.3) | 1 (1.3) | 4 (5.3) | 0.17 |
- Cefazolin | 3 (2.0) | 3 (4.0) | 0 | 0.24 |
- Ceftriaxone | 41 (27.3) | 13 (17.3) | 28 (37.3) | 0.01 |
- Cefepim | 2 (1.3) | 1 (1.3) | 1 (1.3) | n.a. |
- Piperacillin/tazobactam | 20 (13.3) | 13 (17.3) | 7 (9.3) | 0.14 |
- Meropenem | 9 (6.0) | 7 (9.3) | 2 (2.7) | 0.85 |
- Imipenem/cilastatin | 15 (10.0) | 12 (16.0) | 3 (4.0) | 0.01 |
- Vancomycin | 3 (2.0) | 3 (4.0) | 0 | 0.08 |
- Linezolid | 2 (1.3) | 2 (2.7) | 0 | 0.15 |
- Azithromycin | 63 (42.0) | 19 (25.3) | 44 (58.7) | <0.01 |
- Clarithromycin | 1 (0.7) | 1 (1.3) | 0 | 0.31 |
- Levofloxacin | 13 (8.7) | 1 (1.3) | 12 (16.0) | <0.01 |
- Doxicyclin | 10 (6.7) | 0 | 10 (13.3) | <0.01 |
- Gentamicin | 4 (2.7) | 4 (5.3) | 0 | 0.04 |
- Anyb | 108 (72.0) | 47 (62.7) | 61 (81.3) | 0.01 |

Immunomodulatory therapies given (n, %):
- Tocilizumab | 10 (6.7) | 9 (12.0) | 1 (1.3) | 0.01 |
- Ruxolitinib | 0 | 0 | 0 | n.a. |
- Baricitinib | 0 | 0 | 0 | n.a. |
- Intravenous immunoglobulin | 2 (1.3) | 2 (2.7) | 0 | 0.49 |
- Reconvalescent plasma | 0 | 0 | 0 | n.a. |
- Steroid corticosteroid | 3 (2.0) | 3 (4.0) | 0 | 0.24 |

Supportive therapies needed (n, %):
- Nasal cannula | 79 (52.7) | 38 (50.7) | 41 (54.7) | 0.62 |
- Venturi mask | 41 (27.3) | 18 (24.0) | 23 (30.7) | 0.35 |
- Non-invasive ventilation | 4 (2.7) | 4 (5.3) | 0 | 0.12 |
- Non-sedating therapy | 11 (7.3) | 8 (10.7) | 3 (4.0) | 0.11 |
- Renal replacement therapy | 1 (0.7) | 1 (1.3) | 0 | 0.31 |
- Parenteral nutrition | 1 (0.7) | 1 (1.3) | 0 | 0.31 |
- Prone positioning | 3 (2.0) | 0 | 3 (4.0) | 0.24 |
- Any | 89 (59.3) | 43 (57.3) | 46 (61.3) | 0.73 |

n.a., not applicable
aExcluding invasive mechanical ventilation
bAlone or in combination

Although favipiravir demonstrated good in vitro inhibitory activity against SARS-CoV-2, the optimal dose for COVID-19 treatment has yet to be determined, as recommendations are based on pharmacokinetic experiments and earlier clinical trials. Doses extrapolated from studies involving patients with other viral infections (influenza virus, Ebola virus) might be insufficient to maintain adequate serum concentrations, especially in critically ill patients [2, 14, 15]. Although a review found that favipiravir has a favorable safety profile concerning serious adverse events, the main side effects are hyperuricaemia, teratogenicity, and QTc prolongation. Establishment of long-term safety profile
among COVID-19 patients needs more pharma-
vigilance data [16].
Concerning clinical data, clinical usefulness of
favipiravir in COVID-19 may somewhat be limited. A
prospective clinical trial randomizing 240 adult
patients with clinically confirmed COVID-19 to
conventional therapy and umifenovir or favipiravir
reported that although favipiravir associated with
shorter time to defervescence and diminishment
of cough, the drug could not significantly improve
7-day clinical recovery rate as a primary endpoint.
Furthermore, rates of noninvasive mechanical ven-
tilation, supplementary oxygen demand, or all-
cause mortality did not show differences between
groups [4]. An open-label non-randomized study
conducted by matching 35 microbiologically con-
firmed COVID-19 patients treated with favipiravir
and 45 patients receiving lopinavir/ritonavir (all
with interferon-alpha inhalation) within 1 week
after symptom onset found statistically higher
improvement rates in chest imaging and faster
viral clearance among patients receiving favipira-
vir, but effects on disease progression or mortality
were unreported [5]. A recently published phase II/
III randomized trial enrolled patients with moder-
ate COVID-19 within a median of 6.7 days from
symptom start, with a primary endpoint of SARS-
CoV-2 elimination by day 10. On day 5, viral clear-
ance was more prevalent on the favipiravir arm, but
on day 10, this statistical difference diminished.
Authors concluded that favipiravir appeared ben-
eficial among moderately ill patients [17]. In small
case series studies, favipiravir was administered
with nafamostat mesylate or methylprednisolone
for COVID-19 in different stages, but due to anti-
viral combination usage, the extent of favipiravir
effect on clinical cure remains ambiguous [18– 20].
In all, we think that our findings are reflected by
current literature data, and the role for favipira-
vir in the treatment of adults with moderate-to-
severe COVID-19 should probably be interpreted
cautiously.

### Table 3

| Variable                          | Disease progression (n = 27) | No disease progression (n = 123) | Univariate analysis | Multivariate analysis |
|-----------------------------------|----------------------------|---------------------------------|--------------------|-----------------------|
|                                  | Age 74.0 ± 23.1 (41.0–91.0) | 66.0 ± 12.9 (20.0–93.0)         | 1.04 (1.01–10.9)   | 0.01 –                |
| Male gender                       | 12 (44.0)                  | 64 (52.0)                       | 0.74 (0.32–1.72)   | 0.47                  |
| Time from disease onset to antiviral therapy | 3.3 ± 7.8 (1–34)           | 3.5 ± 7.8 (1–34)                | 0.91 (0.81–1.01)   | 0.07* n.a             |
| Chronic heart disease             | 18 (66.7)                  | 34 (27.6)                       | 5.81 (2.32–14.70)  | <0.01 4.27 (1.41–12.98) 0.01 |
| Diabetes mellitus                 | 10 (37.0)                  | 23 (18.7)                       | 2.69 (1.08–6.71)   | 0.03 –                |
| Need for oxygen supportation      | 16 (59.3)                  | 32 (26.0)                       | 4.13 (1.74–9.80)   | 0.01 –                |
| Severe COVID-19                   | 26 (96.3)                  | 50 (27.0)                       | 38.5 (5.0–333.30)  | <0.01 21.28 (2.32–200.0) <0.01 |
| Any supportive therapy needed     | 26 (96.3)                  | 63 (51.2)                       | 5.10 (1.82–14.30)  | <0.01 21.28 (2.32–200.0) <0.01 |
| Any antibacterial therapy needed  | 22 (81.5)                  | 86 (69.9)                       | 1.89 (0.67–5.37)   | 0.23                  |
| Any antiviral therapy needed      | 25 (92.6)                  | 114 (92.7)                      | 1.01 (0.21–4.98)   | 0.98                  |
| Treatment with favipiravir        | 17 (63.0)                  | 58 (47.2)                       | 1.91 (0.81–4.48)   | 0.14 –                |

*n.a.*, not applicable

*The parameter was not included in the final model as co-linearity was not proven by the *Box-Tidwell* test with *Bonferroni*’s post hoc correction (p < 0.01)
Study limitations

Our study had several limitations. As knowledge about COVID-19 is changing at a rapid pace, treatment allocations described in the methods might have been lagging behind evidence despite our best efforts. National drug availability might have affected treatment allocation, while the decision between alternative antiviral agents in the non-FVP cohort might have been biased by contraindication(s). A randomized study design was not feasible during the first wave in Hungary due to ethical concerns. The number of included patients is relatively low; however, an exact a priori study size calculation was not feasible due to study design and consecutive enrollment. Although there are differences between cohorts concerning age and two comorbidities, we hypothesize that this might represent the temporal progression of the epidemic in Hungary, as younger people without comorbidities were mostly affected before FVP became widely available.

Conclusion

Among adult patients hospitalized with moderate-to-severe COVID-19, an overall beneficial effect of favipiravir on disease progression could not be proven in this study. Further trial data are needed to elucidate the role of favipiravir in COVID-19 treatment.

Acknowledgements The following authors from South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, collaborated with the Preparation of the manuscript (Saint Ladislaus COVID-19 Collaborative, in alphabetical order): Zsofia Balogh, Zsuzsanna Banyai, Emese Banyasz, Jozsef Budai, Eszter Czel, Katalin Fried, Adrienn Hanuska, Csaba Lorinczi, Krisztina Nemesi, Janos Kadar, Eva Livia Nagy, Akos Osvald, Edina Petrovicz, Alexandra Riczu, Judit Szanka, Beata Szathmary, Andrea Szombati, Szilvia Toth, Zsuzsanna Varnai, Orsolya Woller. All authors would like to thank the healthcare workers of our center for their sacrifice during these times. Preliminary results of the study were presented at ECCVID 2020 (September 23–25, 2020).

Author contribution BGSz and LKSz contributed equally to the manuscript (in equo loco). BGSZ: management of patients, data collection, data analysis, preparation of study protocol, preparation of the manuscript; LKSZ: management of patients, data collection, data analysis, preparation of study protocol, preparation of the manuscript; BP: data collection, data analysis; ZSG: data collection, data analysis; NKD: data analysis, management of patients, review of the manuscript; JSZ: management of patients, review of the manuscript; IVN: preparation of study protocol, preparation and review of the manuscript; BL: management of patients, preparation of study protocol, preparation and review of the manuscript. Authors of the Saint Ladislaus COVID-19 Collaborative participated equally in patient management and manuscript revision. All authors have read and approved the final manuscript for publication.

Funding Open access funding provided by Semmelweis University. BGSz received the EFOP-3.6.3-VEKOP-16–2017-00009 Doctorate Grant, and was supported by the ÚNKP-19-3.1-SE-74 New National Excellence Program of the Ministry of Innovation and Technology of Hungary. The funding sources had no involvement in the preparation, writing, interpretation, or submission of this article.

Data availability Anonymised data of patients are available from the corresponding author on reasonable request.

Declarations

Ethics approval The study was in accordance with the Helsinki Declaration and national ethical standards. The institutional review board of our center approved the study protocol. Approval for the use of off-label antiviral drugs was granted by the National Institute of Pharmacy and Nutrition and the institutional review board (www.ogyei.gov.hu/tajekoztato_a_veselyhelyyet_megszunesevel_kapcsolatos_a_covid_19_jarvany_idejekunulos_melnyany:e:erdemlo_betegellatasi_erdkekez_kotheto_gyogyszeralkalmazasok_bejelenteserol).

Consent to participate Written informed consent was obtained from each patient.

Conflict of interest The authors declare no competing interests. The ICMJE Form for Disclosure of Potential Conflicts of Interest was completed by the corresponding author on behalf of all co-authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. National Institutes of Health. COVID-19 Treatment Guidelines. 2020. https://www.covid19treatmentguidelines.nih.gov/whats-new/. Accessed 01 Sept 2020.
2. Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.05.15.098731.
3. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75(7):2013–4. https://doi.org/10.1093/jac/dkaa171.
4. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.03.17.20037432.
5. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020. https://doi.org/10.1016/j.eng.2020.03.007.
6. European Centre for Disease Control an Prevention. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020 2020. https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition. Accessed 01 Sept 2020.
7. World Health Organization. Clinical management of COVID-19. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed 01 Sept 2020.
8. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33. https://doi.org/10.1001/jama.2012.5669.
9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/s0140-6736(20)30628-0.
10. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20. https://doi.org/10.1002/art.38690.
11. Emberi Erőforrások Minisztériuma. A 2020. évben azonosított új koronavírus (SARS-CoV-2) okozta fertőzések (COVID-19) megelőzésének és terápiájának kézikönyve. 2020:1–42. [In Hungarian]
12. Metlay JP, Pepperrell T, Hill A. A review of the safety of favipiravir—a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51. https://doi.org/10.1016/s2055-6640(20)30016-9.
13. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1176.
14. Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa K, Sato Y et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: a report of 11 cases. Respir Investig. 2020. https://doi.org/10.1016/j.resp.2020.08.001.
15. Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, Group C-US. Nafamostat mesylate treatment in combination with favipiravir and methylprednisolone for severe COVID-19 pneumonia: a case series. Crit Care. 2020;24(1):392. https://doi.org/10.1186/s13054-020-03078-z.
16. Yamamura H, Matsuura H, Nakagawa J, Fukauka H, Domi H, Chuijoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020;24(1):413. https://doi.org/10.1186/s13054-020-03137-5.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.